Unibest has established a dedicated NewCo structure to accelerate the global out-licensing of its most advanced innovative drug candidates. This structure enables cleaner deal execution, ring-fenced IP ownership, and streamlined equity participation for strategic partners.

The Q3 2025 NewCo pipeline features assets across three therapeutic verticals: immuno-oncology, rare metabolic diseases, and precision psychiatry. All candidates have cleared IND or equivalent regulatory milestones in at least one major jurisdiction.

Licensing terms are structured to accommodate a range of partner profiles — from regional biotech firms seeking territory-specific rights to multinational pharmaceutical companies interested in global co-development agreements.

Unibest's proprietary Digital Intelligence Platform has been used to benchmark valuation for each asset against comparable transactions, providing prospective partners with data-backed deal frameworks. Contact our business development team to access the full pipeline deck under NDA.